Current Developments in Monofocal Intraocular Lens Technology

İlhan, Çağrı

doi:10.17554/j.issn.2409-5680.2017.03.67

Cited by 3 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While the occurrence of PCME has declined with the use of modern surgical techniques, recently developed surgical materials and IOL design, PCME can still occur even following uneventful cataract surgery [15]. Furthermore, the incidence of clinically significant PCME remains around 0.6% to 3.6%, while higher rates have been determined with OCT evidence of CME [51016].…”

Section: Discussionmentioning

confidence: 99%

Intravitreal Dexamethasone Implantation in Intravitreal Bevacizumab Treatment-resistant Pseudophakic Cystoid Macular Edema

Altıntaş

İlhan²

2019

Korean J Ophthalmol

View full text Add to dashboard Cite

Purpose To evaluate the changes in visual acuity (VA) and central macular thickness (CMT) after intravitreal dexamethasone (IVD) implantation in intravitreal bevacizumab (IVB) treatment-resistant cases with pseudophakic cystoid macular edema (PCME). Methods This study included 10 PCME cases who underwent uneventful phacoemulsification and intraocular lens implantation with similar methods and six PCME cases referred to our hospital for treatment of low VA after cataract surgery. Due to the persistence of PCME, both topical steroid and anti-inflammatory medication were administered first, followed by IVB injection. IVD implantation was performed for all IVB treatment-resistant cases. VA and CMT values were compared before and at three months after the first IVD implantation. Results The mean VA values before and at 3 months after the first IVD implantation were 0.69 ± 0.19 logarithm of the minimum angle of resolution (logMAR) (1.50 to 0.10 logMAR) and 0.26 ± 0.07 logMAR (1.00 to 0.00 logMAR), respectively ( p < 0.001). The mean CMT was 476.13 ± 135.13 mm (314 to 750 mm) and 294.06 ± 15.26 mm (222 to 480 mm), respectively ( p < 0.001). The mean number of implanted IVD was 1.44 ± 0.89 (1 to 4) and the mean follow-up time was 7.4 ± 4.6 months (6 to 24 months). After IVD implantation therapy, the mean VA and CMT values were 0.19 ± 0.05 logMAR (0.70 to 0.00 logMAR) and 268.38 ± 31.35 mm (217 to 351 mm), respectively. Conclusions To the best of our knowledge, this is the first report to show the efficacy of IVD implantation even after repeated IVB injections in treatment-resistant PCME. IVD implantation is both a safe and effective method for decreasing PCME after both uneventful and complicated cataract surgery.

show abstract

Section: Discussionmentioning

confidence: 99%

Intravitreal Dexamethasone Implantation in Intravitreal Bevacizumab Treatment-resistant Pseudophakic Cystoid Macular Edema

Altıntaş

İlhan²

2019

Korean J Ophthalmol

View full text Add to dashboard Cite

show abstract

“…Further, acrylic IOLs that are hydrophobic are even less likely to cause PCO and are associated with better capsular biocompatibility than hydrophilic acrylic IOLs 7 . This is why hydrophobic acrylic IOLs are the most commonly used today 8 . Bausch + Lomb's EyeCee® One is a preloaded monofocal hydrophobic acrylic IOL that has aspheric optic, 360-degree posterior square edge, and modified L-loop haptics design features.…”

Section: Introductionmentioning

confidence: 99%

Clinical Safety and Efficacy of a Preloaded Monofocal Hydrophobic Acrylic Intraocular Lens in a Real-world Population

Latham

Carr

Ali

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: This study was designed to evaluate visual, refractive and safety outcomes in eyes after they underwent phacoemulsification and implantation of a preloaded monofocal hydrophobic acrylic intraocular lens.Methods: This was a single center prospective study conducted at Ashford and St Peter’s Hospitals NHS Foundation Trust, United Kingdom. Patients were included if they had cataract extraction with in-the-bag implantation of the EyeCee® One preloaded intraocular lens from August to October 2019. Pre-operative, surgery-related and 2 weeks and 3 months post-operative data was collected. Surgeons at this trust were then asked to complete a feedback form to evaluate their experience of implanting the EyeCee® One. Results: 152 eyes were included in the study. 94 (62%) of these eyes had cataract but no concomitant ocular pathology that could potentially affect visual acuity. Three months post-operatively, 98.7% of all eyes had monocular CDVA ≤ 0.3 logMAR. 100% of the eyes without concomitant ocular pathology achieved this target. The mean CDVA of all eyes in this study improved from 0.43 ± 0.43 logMAR pre-operatively, to 0.05 ± 0.11 logMAR post-operatively (p < 0.05). The mean sphere and spherical equivalent values showed significant improvements (p <0.05) and (p < 0.05). There were no intraoperative complications and 1.3% of patients reported complications 2 weeks post-operatively. All of the participating surgeons said they would use the EyeCee® One again with 64% providing an overall rating of ‘excellent’ for their experience of implanting this intraocular lens. Conclusions: This study indicates excellent post-operative visual acuity and refractive outcomes in eyes after EyeCee® One implantation. This is accompanied with very little risk of intraoperative and post-operative complications.

show abstract

“…Comparative studies have shown that acrylic IOLs with hydrophobic surfaces are even less likely to cause PCO and are associated with better capsular biocompatibility than their hydrophilic counterparts [ 7 , 8 ]. This reduced likelihood of postoperative complications and subsequent correction procedures has led to hydrophobic acrylic IOLs becoming the most used today [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Clinical safety and efficacy of a preloaded monofocal hydrophobic acrylic intraocular lens in a real-world population

et al. 2021

View full text Add to dashboard Cite

Background This study was designed to evaluate visual, refractive and safety outcomes in eyes after they underwent phacoemulsification and implantation of a preloaded monofocal hydrophobic acrylic intraocular lens. Methods This was a single center observational study conducted at Ashford and St Peter’s Hospitals NHS Foundation Trust, United Kingdom. Patients were included if they had cataract extraction with in-the-bag implantation of the EyeCee® One preloaded intraocular lens from August to October 2019. Pre-operative, surgery-related and 2 weeks and 3 months post-operative data was collected. Surgeons at this trust were then asked to complete a feedback form to evaluate their experience of implanting the EyeCee® One. Results One hundred fifty-two eyes were included in the study. Ninety-four (62%) of these eyes had cataract but no concomitant ocular pathology that could potentially affect visual acuity. Three months post-operatively, 98.7% of all eyes had monocular CDVA ≤0.3 logMAR. 100% of the eyes without concomitant ocular pathology achieved this target. The mean CDVA of all eyes in this study improved from 0.43 ± 0.43 logMAR pre-operatively, to 0.05 ± 0.11 logMAR post-operatively (p < 0.05). The mean sphere and spherical equivalent values showed significant improvements (p < 0.05) and (p < 0.05). There were no intraoperative complications and 1.3% of patients reported complications 2 weeks post-operatively. All of the participating surgeons said they would use the EyeCee® One again with 64% providing an overall rating of ‘excellent’ for their experience of implanting this intraocular lens. Conclusions This study indicates excellent post-operative visual acuity and refractive outcomes in eyes after EyeCee® One implantation. This is accompanied with very little risk of intraoperative and post-operative complications.

show abstract

Current Developments in Monofocal Intraocular Lens Technology

Cited by 3 publications

References 26 publications

Intravitreal Dexamethasone Implantation in Intravitreal Bevacizumab Treatment-resistant Pseudophakic Cystoid Macular Edema

Intravitreal Dexamethasone Implantation in Intravitreal Bevacizumab Treatment-resistant Pseudophakic Cystoid Macular Edema

Clinical Safety and Efficacy of a Preloaded Monofocal Hydrophobic Acrylic Intraocular Lens in a Real-world Population

Clinical safety and efficacy of a preloaded monofocal hydrophobic acrylic intraocular lens in a real-world population

Contact Info

Product

Resources

About